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1 INTRODUCTION 
 
1.1 Colorectal cancer. 
 
1.1.1 Origin and epidemiology. 
 
Colorectal cancer (CRC) has the third highest frequency among the 
tumors in the Western world and represents 13% of the causes of 
cancer death in Italy, almost equally split between males and 
females [1, 2]. During the past 20 years, there has been a 
progressive increase in the survival and decrease in mortality, due 
to greater advances in surgical techniques, use of a combination of 
chemotherapy with targeted therapy and campaigns for primary 
and secondary prevention. Unfortunately, in some cases the 
diagnosis of CRC occurs late and after the formation of metastasis, 
which appear at a variable distance from surgery.  
The pathogenesis of CRC is very complex and is influenced by 
multiple factors, some of which are related to diet and lifestyle (i.e. 
smoke, environmental factors, sedentary lifestyle, obesity and/or 
hormones) while others are related to genetic predisposition (i. e. 
Chron’s disease and/or colon polyps) [3]. Indeed, three types of 
CRC can be distinguished by their forms of origin and expression: 
the sporadic form (60-80%), the familial (10-20%) and the 
hereditary type (15%), which can be associated with familial 
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adenomatous polyposis (FAP) or not associated with polyposis, 
hereditary nonpolyposis CRC (HNPCC) [4]. 
 
1.1.2 Molecular and genetic features. 
 
Even at the molecular level, CRCs are a very heterogeneous group 
of diseases and progress in a stepwise manner through 
dysregulation of various pathways [5]. Chromosomal instability 
(CIN), microsatellite instability (MSI), aberrant DNA methylation 
and DNA repair defects are all mechanisms involved in colorectal 
epithelial cell transformation and all play a significant role during 
the development of CRCs [6]. Moreover, during cancer 
development, epithelial cells from the gastrointestinal trait acquire 
sequential genetic and epigenetic mutations in oncogenes and/or 
tumor suppressor genes, leading to proliferation and metastasis 
(Figure 1). 
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Figure 1. Sequential genetic and epigenetic mutations acquired during 
neoplastic transformation from normal intestinal epithelium to colorectal 
carcinoma [5]. 
 
 
Several altered molecular signaling pathways are involved in CRC 
initiation and progression, such as Wnt/APC/b-catenin, 
PI3K/AKT/mTOR, RAS/RAF, MAPK pathways, p53 and 
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mismatch repair (MMR) [7].  APC gene mutations have been 
detected in 60% of sporadic colon cancers, FAPs and variants, 
although their distribution within the gene is different [8].  
KRAS is involved in CRC initiation and progression, with 
mutations occurring quite early in 40-60% of cases and its 
mutations are identified as mechanisms of resistance to anti-EGFR 
monoclonal antibodies (cetuximab and panitumumab), which are 
currently used in therapy [9]. RAS family includes also HRAS and 
NRAS: NRAS mutations are found in about 3-5% of CRC and also 
contribute to EGFR-antibodies resistant mechanisms development 
[10]. Further studies have also shown that KRAS mutations are not 
the same: indeed, as opposed to KRAS G12V, patients with mutation 
in the KRASG13D codon on exon 2 may respond to EGFR 
monoclonal antibodies, although not to the same extent as the 
patients with wild-type (wt) KRAS [11]. Activating mutations in 
BRAF have been found in about 10% of sporadic CRC and are rare 
in familiar CRC. Patients with BRAFV600E mutation appear to have 
a poorer prognosis: indeed, BRAF is downstream of activated 
KRAS protein in the EGFR pathway, so the constitutive activation 
of BRAF renders therapeutic inhibition of EGFR ineffective. 
Moreover, when KRAS, BRAF, PI3K, and PTEN, the downstream 
effectors of EGFR signaling, are not mutated (quadruple negative) 
cetuximab and panitumumab show the best response in CRC [12].  
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Many cancer types are associated with alterations of receptor 
tyrosine kinases (RTKs), which are the first receivers of 
extracellular signals. EGFR is considered a proto-oncogene, but 
somatic EGFR mutations are found in less than 5% of CRC [13]. 
Activating mutations in PIK3CA, the gene encoding the catalytic 
subunit of PI3K, are somatically mutated in over 25% of CRC and 
represent an alternative EGFR-mediated signaling pathway [14]. 
PI3K signaling is deregulated through a variety of mechanisms, 
including the loss of phosphatase and tensin homolog deleted on 
chromosome 10 (PTEN), which ranges from 4 to 40 % of all 
CRCs. In patients with CRC, promoter hypermetilation, decreased 
DNA copy number and reduction of protein expression, all concur 
to causing an increasing inactivation of PTEN: as a consequence, 
loss of PTEN expression has been shown to be associated with the 
occurrence of metastasis and progression of disease [15]. 
More recently it has been discovered that also microRNA 
(miRNA) can actively contribute to angiogenesis, cell invasion and 
metastasis in CRC [16]. This complex network of different 
pathways, genetic and/or epigenetic changes, with the presence of 
a strong chronic inflammation are all involved in the pathogenesis 
of CRC, underlying the complexity of potential new biomarkers 
identification [17]. 
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1.2 Inflammation and microenvironment. 
 
A major contributor to the limited therapeutic success achieved by 
only targeting tumor cells is the tumor microenvironment (TME), 
with inflammation and inflammatory mediators. The connection 
between inflammation and tumorigenesis is well-established and in 
the last decade has received a great deal of supporting evidence 
from genetic, pharmacological, and epidemiological data. To date, 
it is clear that tumor stroma (including fibroblasts, inflammatory 
cells and endothelial cells) plays an important role in promoting 
tumor progression, however many of the mechanisms underlying 
tumor-stroma interaction (TSI) are to be identified. 
Tumor stroma consists of the non-malignant cellular component of 
the tumor, such as cancer-associated fibroblasts (CAFs), tumor-
infiltrating cells, vasculature with endothelial cells and the 
extracellular matrix (ECM) consisting of structural proteins and 
other matrix-associated molecules, such as growth factors, 
chemokines and cytokines [18]. Solid tumors are commonly 
infiltrated by immune cells, including T cells, B cells, natural killer 
(NK) cells, macrophages, dendritic cells (DCs), neutrophils, 
eosinophiles, basophiles and mast cells. Macrophages are a major 
component of innate immune cells and they are an example of how 
the immune system can act as a tumor suppressor disrupting cancer 
cells recognized as non-self on one hand and of how tumors can 
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derive benefits for survival and proliferation from the immune 
system itself on the other [19]. Indeed, macrophages have dual 
roles in neoplastic progression: they inhibit tumor growth by 
secreting lytic enzymes such as lysosomal enzymes and TNF-a 
after activation, but a distinct M2 polarized population promotes 
tumor cell proliferation and angiogenesis, tumor invasion and 
metastasis [20].  
Many studies have contributed to the characterization of TME and 
it is now evident that tumors differ by mutations and also by their 
microenvironmental composition, and stromal cell proportions or 
activation states [21]. Numerous cell culture studies and xenograft 
models have shown evidence that mesenchymal stromal cells 
(MSCs) are recruited into the tumor site, as it happens during the 
healing process of wounds and scarring: in this way, inflammation 
promotes cancer progression and cell proliferation [22]. Similarly 
to MSCs, also CAFs, through the secretion of growth factors and 
chemokines, induce an extracellular matrix alteration and provide 
further oncogenic signals of proliferation and invasion to cancer 
cells [23]. The active contribution of tumor-associated stromal 
cells in tumor progression is well-known and the inflammatory 
cytokines, released by both cancer and stromal cells, may act as an 
initiator and promoter of carcinogenesis by directly increasing 
proliferation of epithelial cells [24]. In response to specific 
chemokines, different immune cell subsets migrate into the tumor 
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microenvironment and regulate tumor immune responses; for 
example, CD8+ T and NK cells are recruited by CXCL9 and 
CXL10, regulatory T (Treg) cells by CCL22, released mainly by 
macrophages and tumor cells, or macrophages by CCL2-CCR2 
signaling [25]. 
Not only TME promotes cancer invasion and metastasis, but it also 
provides resistance to chemotherapy, and cancer cells upregulate 
chemokines expression proportionally to the progression of the 
disease. Although currently there is no therapy targeting 
chemokines to prevent CRC invasion and/or metastasis, 
understanding the mechanisms involved in TSI thoroughly in order 
to achieve a comprehensive therapy in advanced and metastatic 
CRC remains crucial [26]. 
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Figure 2. Signaling of chemokines in TSI [26]. 
 
 
1.3 Interleukin-8. 
 
1.3.1 Roles and regulation of IL-8 expression. 
 
Chemokines, a family of structurally related 8-10 kDa proteins, are 
secreted in several tissue environments and are involved in the 
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regulation of inflammatory processes [27]. Chemokines are 
divided in 4 subfamilies (C, CC, CXC and CX3C) based on their 
primary structure and function: all have the main cysteine residues 
in their N-terminal regions. 
Interleukin-8 (IL-8), alternatively known as CXCL8, is a pro-
inflammatory CXC chemokine containing the ELR (Glu-Leu-Arg) 
motif, associated with the promotion of neutrophil chemotaxis and 
degranulation [28]. Indeed, IL-8 is also known as “neutrophil 
chemotactic factor”, because of its role in inducing chemotaxis in 
target cells, primarily neutrophils but also other granulocytes, 
causing them to migrate toward the site of infection [29]. IL-8 
plays another important role in angiogenesis through stimulation of 
endothelial cell migration and upregulates the expression of the 
two metalloproteases MMP-2 and MMP-9 [30]. 
Expression of IL-8 is upregulated by hypoxia, cytokine and other 
environmental stresses, which is mediated by the transcription 
factors nuclear factor kappa B (NF-kB) and activating protein-1 
(AP-1) [31]. It was demonstrated that the IL-8 promoter element 
contains NF-kB, AP-1, transcription factors C/EBP homologous 
protein (CHOP) and cAMP response element binding 
protein (CREB) binding sites [32]. NF-kB is essential for 
activation of IL-8 transcription, while AP-1 and CHOP are 
required for maximal IL-8 expression by synergizing with NF-kB 
in a cell-dependent manner [33]. All three mitogen- activated 
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protein kinase (MAPK) pathways (ERK1/2, JNK and p38) activate 
AP-1 and contribute to IL-8 gene expression [34]. In glioblastoma 
cell, it has been demonstrated that IL-8 is also a direct target of 
STAT3: in the presence of the tumor suppressor PTEN, STAT3 is 
activated by phosphorylation, binds to the IL-8 promoter, and 
represses IL-8 gene expression [35]. Also in prostate carcinoma, it 
has been demonstrated that PTEN loss induces a selective 
upregulation of IL-8 signaling [36].  
There is an adenosine and uridine (AU)-rich RNA instability 
element (AUUUA) present in the 3' untranslated region of the IL-8 
mRNA, that contributes to its having a short half-life: stabilization 
of the IL-8 mRNA is another point of IL-8 expression regulation, 
which is mediated by p38 MAPK [37]. The expression of IL-8 
mRNA produces a precursor peptide of 99 amino acids, which then 
undergoes cleavage to yield the active IL-8 isoforms, a 77 amino 
acids in nonimmune cells or 72 amino acids in monocytes and 
macrophages [38]. 
 
1.3.2 IL-8 signaling. 
 
The biological effects of IL-8 are mediated through the binding of 
IL-8 to two cell-surface receptors, the seven transmembrane G-
protein-coupled receptors CXCR-1 (IL-8RA) and CXCR-2 (IL-
8RB), which are present in various type of normal as well as tumor 
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cells [39]. These receptors share 77% amino acid homology and 
retain common structural motifs, suggesting that these genes arose 
through gene duplication [40]. CXCR1 is activated by IL-8 and 
granulocyte chemotactic protein-2 (GCP-2)/CXCL6, whereas 
CXCR2 can be activated not only by IL-8 but by many other CXC 
chemokines [41]. 
Ligand-receptor binding determines conformational changes, 
which allow the exposure of epitopes on the intracellular loops and 
carboxy-terminal tail of the receptor that promote coupling to 
functional heterotrimeric G proteins, which consist of α, β, and γ 
subunits. Ligand binding catalyzes the exchange of guanosine 
diphosphate for guanosine triphosphate on the Gα subunit, which 
triggers the release of this subunit from the receptor and the Gβγ 
subunits and consequently, signals are transmitted across the 
membrane and activate downstream effectors [42]. The principal 
effector of IL-8-mediated chemotaxis in neutrophils is the kinase 
phosphatidyliinnositol-3 (PI3K): the phosphorylation of 
phosphatidyliinnositol-2-phosphate (PIP2) in 
phosphatidyliinnositol-3-phosphate (PIP3) results in the activation 
and increased expression of the serine/threonine kinase AKT [43]. 
IL-8 signaling also regulates the activity of the MAPK signaling 
cascade, RAS/RAF/MEK/ERK. Activation of MAPK signaling 
and the downstream phosphorylation of ERK1/2 determines cell 
proliferation and cell survival, both in neutrophils and cancer cells 
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[44]. In prostate cancer models, it has been demonstrated that IL-8 
mediates growth and cell migration effects via Src and FAK 
activation [45]. Moreover, IL-8 signaling induces vascular 
endothelial growth factor (VEGF)-independent tumor angiogenesis 
and chemotaxis of neutrophils to the tumor site via its paracrine 
activity [46]. 
IL-8 promotes proliferation, survival and migration of cancer cells 
via its autocrine and paracrine activity and all these pathways are 
involved in cancer cell survival, proliferation, mobility and 
invasiveness: in this way, IL-8 signaling is involved in a complex 
communication between tumor cells and tumor microenvironment, 
through both paracrine and autocrine mechanisms [47]. 
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Figure 3. Principal signaling pathways activated by IL-8-CXCR1/2 binding, to 
regulate cell survival, proliferation, angiogenesis and metastasis [28]. 
 
 
1.3.3 Role of IL-8 in CRC progression and metastasis. 
 
In addition to its physiological roles in chemotaxis, IL-8 is 
implicated in many processes involved in cancer progression, of 
several different histological types of tumor such as prostate, 
colorectal, lung cancer and melanoma. IL-8-mediated neutrophil 
recruitment to the tumor site can facilitate tumor progression and 
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clinical studies have correlated intra-tumoral neutrophils with poor 
prognosis in colorectal and multiple cancer [48]. 
In CRC patients, IL-8 expression is upregulated in tumor tissue 
compared with the adjacent healthy colonic tissue [49]. Moreover, 
germline polymorphisms of IL-8 and VEGF are associated with a 
higher risk of developing tumor recurrence in stage III CRC 
patients [50]. Elevated serum levels of several cytokines secreted 
mainly by tumor cells and by CAFs have a prognostic value and 
are also implicated in tumor aggressiveness and poor response to 
therapy: indeed, high levels of IL-8 in serum of patients correlate 
with a more advanced tumor stage [51]. Furthermore, treatment 
with an inhibitor of CXCR2, SCH-527123, alone and in 
combination with oxaliplatin, is effective in synergistically 
inhibiting proliferation, angiogenesis, and enhancing chemo-
sensitivity in CRC cells and xenografts [52]. 
A significant number of in vitro and in vivo pre-clinical studies 
support the importance of IL-8-CXCR1/2 signaling in promoting 
tumor progression and multiple small-molecule antagonists and 
humanized monoclonal antibodies are under investigations [53]. 
Based on these evidences, IL-8 and its receptors may represent a 
novel therapeutic target in CRC, to sensitize cancer cells toward 
chemotherapy [54]. 
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2 AIM OF THE STUDY. 
 
Both tumor growth and response to antineoplastic drugs are 
affected by the microenvironment: investigating the stromal 
contribution is crucial for the development of new therapeutic 
strategies, as suggested, for example, by the use of chemotherapy 
plus bevacizumab, a VEGF inhibitor, in the treatment of colorectal 
carcinoma. In addition to VEGF, many recent studies demonstrate 
that IL-8 plays a key role in cancer progression and 
metastatization, in many cancer models (including CRC), thus 
providing additional possibilities for targeted intervention. 
We previously demonstrated that PTEN-loss predicts synergistic 
growth-inhibitory interactions between RAF/MEK and 
PI3K/AKT/mTOR inhibitors, in a panel human cancer cell lines of 
different histological origin, including CRC [55]. Moreover, 
preliminary results show that in an isogenic CRC cell lines only 
differing for PTEN status, IL-8 is over-expressed in PTEN-/-.  
The aim of the study is to investigate how the specific genetic 
background of CRC cells influences their expression of 
chemokines and proangiogenic factors, such as IL-8, and how 
these are modulated in response to different signaling inhibitors 
(BRAF, MEK, ERK1/2, PI3K/AKT). First, we quantitatively 
analyzed chemokines and cytokines released into the culture 
medium of different CRC cell lines, under standardized culture 
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conditions to overcome the possibility that different number of 
cells alter the expression of chemokines. Next, we evaluated the 
effect of different drugs (trametinib, dabrafenib and gedatolisib) on 
chemokine production in different specific genetic backgrounds. 
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3 MATERIALS AND METHODS 
 
3.1 Cell lines.  
 
CRC cell lines were kindly provided from Federica Di 
Nicolantonio (University of Turin, Turin, Italy) [56]. X-MAN™ 
HCT116 Parental and HCT116 PTEN-/- were generated by Horizon 
from homozygous knock-out of PTEN by deleting exon 5 which 
encodes the active site of the protein in the CRC cell line HCT116 
(Horizon Discover www.horizondiscovery.com). Isogenic cell 
lines HCT116, HK2-6 and HKE-3 and DLD-1, DKO-1 and DKO-4 
were performed by Shirasawa’s group by gene targeting technique 
[57]. 
Cell lines were routinely maintained in RPMI 1640 or DMEM 
medium supplemented with 10% fetal bovine serum (FBS), 2 mM 
L-glutamine, and antibiotics (Pen/Strep) in a humidified 
atmosphere with 5% CO2 at 37 °C. For hypoxic treatment, cells 
were incubated for 24 hours in specially designed aluminum 
chambers, flushed with a gas mixture containing 5% CO2 and 95% 
N2 (Biroccio A. et l., 2000). Cell culture reagents were purchased 
from Euroclone and Invitrogen (Milan, Italy). 
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3.2 Drug treatments.  
 
Trametinib (GSK1120212) and dabrafenib (GSK2118436) were 
kindly provided by GlaxoSmithKline (Brentford, Middlesex, UK). 
Gedatolisib (PF05212384) was kindly provided by Pfizer Inc. 
(New York, NY, USA). Trametinib and gedatolisib were dissolved 
in DMSO as a 1 mM stock solution and stored at -20°C or -80°C, 
respectively. Dabrafenib was dissolved in DMSO as a 10mM stock 
solution and stored at -20°C. SCH772984 was purchased by 
Selleck Chemicals and dissolved in DMSO as 0.2 mM stock 
solution and stored at -20°C. Stattic and S3I-201 were purchased 
by Selleck Chemicals and dissolved in DMSO as 5 mM stock 
solution and stored at -80°C. 
The final concentration of drugs was obtained by dilution with 
culture medium. 
 
3.3 Cell viability assay. 
 
For cell counting, Thoma chamber was used. Effects on cell 
growth in response to different treatments were monitored by 
Crystal Violet assay. For Crystal Violet assay, a fixed number of 
tumor cells were dispensed into 24-wells (NEST Biotechnology), 
and the following day cells were treated at indicated concentrations 
of drugs. After 72 hours of treatment, the cells were washed with 
PBS, fixed with 4% formaldehyde for 10 minutes and then stained 
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with 0.1% crystal violet for 40 minutes, at room temperature. 
Excess stain was removed with water and the plates were dried. 
Crystal violet stain was extracted with 95% acetic acid and the 
absorbance was measured at 570 nm. 
The dose of drug that causes 50% of cell growth inhibition (IC50 
value) was calculated according to the Chou-Talalay method using 
the Calcusyn software (Biosoft, Cambridge, United Kingdom). 
 
3.4 Standardization and assessment of cell culture 
media. 
 
 In order to overcome the possibility that a different number of 
cells alter the results in the analysis of the chemokines, growth 
curves for each CRC cell line were assessed at different cell 
concentrations to evaluate their growth. 
Standardization: All cell lines were plated into 60x15 dishes 
(Falcon BD) to have about 1x106 cells after 48 hours of plating. 
After 24 hours from the plating, the culture medium was replaced 
by serum-free medium, and after 24 hours, media were collected 
and cells were counted.  
Assessment: CRC cell culture media were analyzed in triplicate as 
per the manufacturer's instructions using human IL-8, IL-6 and 
VEGF specific ELISA, purchased from Enzo Life for IL-8 and IL-
6 analysis and from R&D Systems for VEGF. Absorbance was 
read at 450 nm.  IL-8, IL-6 and VEGF expression was represented 
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as pg/mL and then related to the control. HCT116 Parental and 
HCT116 PTEN-/- culture media were analyzed by Human 
Angiogenesis Antibody Array, according to the manufacturer's 
protocol. 
 
3.5 Western blot analysis.  
 
Whole cell extracts were obtained by NP-40 lysis buffer, 
containing 50 mmol/L Tris-HCl (pH 8.0), 250 mmol/L NaCl, 1 
mmol/L EDTA, 100 mmol/L NaF, 1 mmol/L NaVO4, 10 mmol/L 
PMSF, 10 µg/mL leupeptin, 1% NP40. Assay sample for protein 
concentration used was BCA (Protein Assay Reagent A, Protein 
Assay Reagent B 50x, Pierce). An amount of total cell lysate was 
fractionated by SDS-polyacrylamide gel electrophoresis and 
transferred to nitrocellulose membrane (Amersham, Arlington 
Heights, USA). Membranes were probed with the following 
primary antibody: phosphorylated (Thr202/Tyr204) and total 
ERK1/2, PTEN, phosphorylated (Ser727 and Tyr705) and total 
STAT3 (from Cell Signaling Technology Inc. Beverly, USA). 
Signal was detected using peroxidase-conjugated anti-mouse or 
anti-rabbit secondary antibodies (Jackson Immunoresearch Labs, 
Inc., Baltimore, USA). The enhanced chemi-luminescence (ECL) 
system (Amersham) was used for detection and image detection 
was performed with UVITEC Alliance 4.7 system (Cambridge, 
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UK). To control the amount of proteins transferred to 
nitrocellulose membrane β-actin was used and detected by anti β-
actin mAb (clone AC-15, Sigma, St. Louis, USA). 
 
3.6 RNA analysis.  
 
Total RNA was prepared from cells using the RNA extraction kit, 
RNeasy Mini Kit (Qiagen) as per the manufacturer's instructions. 
Of total RNA, 1 µg was converted into single-strand cDNA using 
Superscript II (Invitrogen) as per the manufacturer's instructions. 
Quantitative real-time PCR (qRT-PCR) was performed with Fast 
SYBR®Green quantitative PCR kit (Applied) for RPL19 (Forward 
primer sequence: 5'-CGGAAGGGCAGGCACAT-3' and Reverse 
primer sequence 5'-GGCGCAAAATCCTCATTCTC-3'), IL-8 
(Forward primer sequence: 5’-AGGGTTGCCAGATGCAATAC-
3’ and Reverse primer sequence 3’-
CCTTGGCCTCAATTTTGCTA-5’) and PTEN (Forward primer 
sequence: 5'-AATAAAGACAAAGCCAACCGATACTT-3' and 
Reverse primer sequence 5'-CGGCTCCTCTACTGTTTTTGTGA-
3'). Expression of PTEN and IL-8 mRNA was then normalized 
with RPL19 and PTEN was compared with mRNA positive control 
of T98G. 
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3.7 Statistical analysis.  
 
Results are expressed as median (range). Optimal cut-off and 
performance characteristics (sensitivity, specificity, areas under the 
curves-AUC) were evaluated by computing Receiver Operating 
Chacteristic (ROC) curves. The associations between variables 
were tested by Pearson Chi Square test or Fisher exact test, when 
appropriate. The SPSS® (21.0), R® (2.6.1), MedCalc® (13.0) 
statistical programs were used for all analyses. P-value of <0.05 
was considered statistically significant. 
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4 RESULTS 
 
4.1 PTEN profiling in human CRC.  
 
First, we characterized a panel of 29 CRC cell lines for both PTEN 
mRNA and protein levels, by RT-qPCR and Western blotting, 
respectively. T98G were used as a positive control for both PTEN 
mRNA and protein expression. In order to overcome the 
possibility that a different number of cells may alter the levels of 
PTEN expression, we normalized the cell growth: all the cell lines, 
indeed, were seeded to have about one million of cells after 48 
hours from plating and the media was replaced by serum-free 
media after 24 hours from plating.  
As shown in Figure 1 and summarized in Table 1, PTEN protein 
expression was completely absent (score 0, - in Table 1) in 11 CRC 
cell lines, weak (score 0.1–0.3, + in Table 1) in 1, moderate (score 
0.3–0.6, + + in Table 1) in 7, and strong (score 0.6–1, + + + in 
Table 1) in 10 of the tested cell lines. Ratio of PTEN antibody/β-
actin for each individual sample was compared with the positive 
control T98G (1.0). For PTEN mRNA analysis, results were 
evaluated as ΔΔct of PTEN mRNA relative to RPL19 and 
expressed as the ratio, assuming the levels in T98G positive control 
cells as 1.0 (Figure 3 and Table 1).  
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Cell lines carrying PTEN deletions or inactivating mutations or 
completely lacking PTEN protein expression (score 0) are referred 
to as PTEN-loss.  
 
 
 
Figure 3. PTEN expression in 29 CRC cancer cell lines. A. Cells were lysed 
and analyzed by Western Blotting using antibodies specific for PTEN. Western 
blot with antibody specific for β-actin are shown as protein loading and blotting 
control. T98G cells were used as a positive control for PTEN expression. B. The 
presence of PTEN was detected by real-time PCR in all cell lines. Results were 
evaluated as ΔΔct of PTEN tested relative to RPL19 and expressed as the ratio 
assuming the levels in T98G positive control cells as 1.0. Results are 
representative of an experiment of two independent experiments. 
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Table 1. Characterization of 29 CRC cell lines 
 
 
Table 1. PTEN status in 29 CRC cell lines. *OD ratio of PTEN antibody/β-actin 
for each individual sample is compared with OD of positive control T98G. + 
score 0.1–0.3; + + score 0.3–0.6; + + + score 0.6–1. **Results represent PTEN 
mRNA abundance relative to positive control T98G.  
Cell line BRAF KRAS PI3K PTEN 
PTEN 
Protein 
expression* 
Relative 
PTEN 
mRNA 
abundance 
** 
MSDT8 p.V600K wt wt p.D310G - 0.00 
LIM2537 p.V600E wt Del ex9  - 0.20 
LIM2412 p.V600E wt wt  - 0.13 
LS411N p.V600E wt wt  - 0.10 
SNU-C4 wt wt 
p.E545G 
ex9 p.F241S - 0.62 
SNU-C5 p.V600E wt p.H1047R  ++ 0.78 
SNU1040 wt wt wt p.L70_splice - 0.05 
SNU1544 wt wt p.H1047R  ++ 0.21 
SNU1047 wt wt wt p.K267fs*9 - 0.15 
SNU1235 p.V600E wt wt  - 0.11 
HCT116 Parental wt p.G13D etero p.H1047R  ++ 0.21 
HCT116 PTEN-/- wt p.G13D p.H1047R  - 0.11 
HCT116 Shirasawa wt p.G13D omo p.H1047R  +++ 0.23 
HCT116 HK2-6 wt p.G13D omo p.H1047R  ++ 0.36 
HCT116 HKE-3 wt wt p.H1047R  ++ 0.21 
DLD-1 wt p.G13D etero p.E545K  +++ 0.38 
DLD-1 Shirasawa wt p.G13D omo p.E545K  + 0.28 
DKO-1 wt p.G13D omo p.E545K  +++ 0.33 
DKO-4 wt wt p.E545K  +++ 0.36 
KM12C wt wt wt  - 0.19 
VACO432 p.V600E wt wt  +++ 0.32 
HT29 p.V600E wt wt  +++ 0.54 
LS180 wt p.G12D ex2 p.H1047R p.I67K +++ 0.46 
SW620 wt p.G12V wt  +++ 0.39 
SW480 wt p.G12V wt  ++ 0.12 
COLO205 p.V600E wt wt  +++ 0.37 
RKO p.V600E wt p.H1047R  ++ 0.11 
COGA3 wt p.G13D ex2 wt  - 0.3 
HROC87 p.V600E wt wt  +++ 0.29 
 
Table 1. PTEN status in 29 colorectal cancer cell lines. *OD ratio of PTEN antibody/β-actin for each 
individual sample is compared with OD of positive control T98G. + score 0.1–0.3; + + score 0.3–0.6; 
+ + + score 0.6–1. **Results represent PTEN mRNA abundance relative to positive control T98G. 
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4.2 BRAFV600E and PTEN-loss are significantly 
associated with IL-8 production.  
 
To investigate the role of PTEN status in modulating the 
expression of pro-angiogenic cytokines/chemokines, cell culture 
media of X-MAN™ isogenic HCT116 cell lines (HCT116 Parental 
and HCT116 PTEN-/-) were analyzed by Human Angiogenesis 
Antibody Array after 24 hours of culture in serum-free medium. As 
shown in Figure 4A, IL-8 was selectively expressed, suggesting 
that PTEN may be a genetic determinant of IL-8 expression, in 
HCT116 PTEN-/-. We also confirmed the selective production of 
IL-8 only in PTEN-/- context by ELISA assay (Figure 4A bottom 
panel).  
To asses a potential correlation between tumor cell genetic 
background and IL-8 production, cell culture media of twenty-nine 
CRC cell lines with different genetic background and PTEN 
protein expression (BRAFV600E=11; KRASG13D/G12V=8; 
PI3KH1047R/E545G/P124T=11; PTEN-loss=11, Table 1) were analyzed 
by ELISA assay under standardized culture conditions (Figure 4B-
C) and the results were expressed as pg/mL for 1x106 cells.   
Statistical analysis showed a statistically significant correlation 
between the expression of IL-8 and BRAFV600E: indeed, BRAF 
mutation predicts IL-8 levels higher than 257.5 pg/mL (cut-off 
levels) with 58.33% sensitivity and 93.75% specificity (area under 
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ROC curve, AUC=0.76) and the ROC curve-based prediction 
algorithm based on BRAF mutation had 52% accuracy in 
predicting IL-8 production (p=0.004) (Figure 5A). Statistical 
analysis also showed a trend towards a statistically significant 
association with PTEN-loss: indeed, PTEN-loss predicts an IL-8 
value higher than 42.5 pg/mL with a 64.29% sensitivity and 
78.57% specificity (AUC=0.71) and the ROC curve-based 
prediction algorithm based on PTEN-loss had 43% accuracy in 
predicting IL-8 production (p=0.05) (Figure 5B). Moreover, the 
highest levels of IL-8 are observed in CRC cell lines carrying both 
BRAFV600E and PTEN-loss (n=5): indeed, combined BRAF/PTEN 
analysis predicts an IL-8 value higher than 46 pg/mL with 87.50% 
sensitivity and 80.00% specificity (AUC=0.88) and the ROC 
curve-based prediction algorithm based on these two alterations 
had 68% accuracy in predicting IL-8 production (p=0.002) (Figure 
5C). 
KRAS and PI3K status did not show correlation with IL-8 
expression (data not shown). 
These results support the hypothesis that PTEN status modulates 
CRC chemokine expression profile, and demonstrate that both 
BRAF and PTEN status are crucial determinant of the expression 
of IL-8, in model systems in vitro. 
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Figure 4. IL-8 expression in 29 CRC cell lines. A. Cell culture media of 
HCT116 Parental and HCT116 PTEN-/- were analyzed by both Human 
Angiogenesis Antibody Array (in the rectangle in blue is shown the expression 
of IL-8) and IL-8 ELISA assay (reported as % of control). B. 29 cell culture 
media, divided by the status of PTEN and BRAF, were analyzed by IL-8 ELISA 
assay; the results are expressed as pg/mL for 1x106 cells. P-value of <0.05 is 
considered statistically significant. C. 29 CRC cell lines analyzed for their 
relative IL-8 expression (shade of blue) and their genetic background of BRAF, 
KRAS and PI3K or PTEN protein lack expression (reported in red). Results 
represent the average of three independent experiments. 
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Figure 5. IL-8 is more expressed in CRC cell lines BRAFV600E/PTEN-loss. A. 
BRAFV600E analysis predicts high IL-8 production > 257.5 pg/mL, with 58.33% 
sensitivity, 93.75% specificity and 52%accuracy, p=0.004. B. PTEN-loss 
analysis predicts high IL-8 production > 42.5 pg/mL, with 64.29% sensitivity, 
78.57% specificity and 43% accuracy, p=0.05. C. Combined BRAFV600E/PTEN-
loss analysis predicts high IL-8 production > 46 pg/mL, with 87.50% sensitivity, 
80.00% specificity and 68%accuracy, p=0.002.  
 
 
4.3 Analysis of VEGF and IL-6 expression.  
 
In order to assess whether the production of other chemo- and 
cytokines involved in CRC initiation and progression also 
correlates with BRAF and PTEN status, the same analysis was 
performed for VEGF and Interleukin-6 (IL-6). 
VEGF levels were correlated with BRAF/KRAS mutational status 
and PTEN expression, under normo- and hypoxic conditions of 
growth. The results expressed as pg/mL for 1x106 cells were 
analyzed by Pearson Chi Square test. As shown in Figure 6 and 7, 
both PTEN-loss and absence of KRAS mutations significantly 
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correlated with higher levels of VEGF under both normoxic and 
hypoxic conditions, whereas BRAF mutational status had a 
borderline significant association with higher basal levels of VEGF 
under normoxia (p=0.05) and was not associated with hypoxia-
induced VEGF production. Indeed, in normoxia, PTEN-loss 
predicts a VEGF value higher than 621 pg/mL with a 92.86% 
sensitivity and 57.14% specificity (AUC=0.77) and the ROC 
curve-based prediction algorithm based on PTEN-loss had 50% 
accuracy in predicting VEGF production (p=0.01) (Figure 8A, left 
panel). KRASG13D/G12V predicts a VEGF value lower than 627 
pg/mL with a 75% sensitivity and 80% specificity (AUC=0.75) 
and the ROC curve-based prediction algorithm based on 
KRASG13D/G12V had 55% accuracy in predicting VEGF production 
(p=0.01) (Figure 8A, right panel). Similarly, in hypoxia, PTEN-
loss predicts a VEGF value higher than 1012 pg/mL with a 92.86% 
sensitivity and 61.54% specificity (AUC=0.72) and the ROC 
curve-based prediction algorithm based on PTEN-loss had 54% 
accuracy in predicting VEGF production (p=0.004) (Figure 8B, left 
panel). KRASG13D/G12V predicts a VEGF value lower than or equal 
to 1046 pg/mL with a 75.00% sensitivity and 78.95% specificity 
(AUC=0.76) and the ROC curve-based prediction algorithm based 
on KRASG13D/G12V had 54% accuracy in predicting VEGF 
production (p=0.02) (Figure 8B, right panel). 
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These results suggest that VEGF is differentially expressed on the 
basis of KRAS and PTEN, but not of BRAF status, regardless of 
the cell growth condition (normoxia versus hypoxia). PI3K status 
is not correlated with VEGF expression (data not shown). 
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Figure 6. VEGF expression in 29 CRC cell lines, under normoxic condition 
of growth. 29 cell culture media, divided by the status of PTEN (A), KRAS (B) 
and BRAF (C), were analyzed by VEGF ELISA assay; the results are expressed 
as pg/mL for 1x106 cells. P-value of <0.05 is considered statistically significant. 
D. 29 CRC cell lines analyzed for their relative VEGF expression (shade of 
blue) and their genetic background of BRAF, KRAS and PI3K or PTEN protein 
lack expression (reported in red). Results represent the average of three 
independent experiments. 
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Figure 7. VEGF expression in 29 CRC cell lines, under hypoxic condition of 
growth. 29 cell culture media, divided by the status of PTEN (A), KRAS (B) 
and BRAF (C), were analyzed by VEGF ELISA assay; the results are expressed 
as pg/mL for 1x106 cells. P-value of <0.05 is considered statistically significant. 
D. 29 CRC cell lines analyzed for their relative VEGF expression (shade of 
blue) and their genetic background of BRAF, KRAS and PI3K or PTEN protein 
lack expression (reported in red). Results represent the average of three 
independent experiments. 
 
 
 
 
Dottorato di ricerca in Oncologia 
  Pag. 39  
 
            
Figure 8. VEGF is more expressed in CRC cell lines with PTEN-loss, 
whereas it is lower expressed in KRASG13D/G12V. A. PTEN-loss analysis 
predicts VEGF production > 621 pg/mL, with 92.86% sensitivity, 57.14% 
specificity and 50%accuracy, p=0.01 (left panel) and KRASG13D/G12V analysis 
predicts VEGF production < 627 pg/mL, with in normoxic condition of growth. 
B. PTEN-loss analysis predicts VEGF production > 1012 pg/mL, with 92.86% 
sensitivity, 61.54% specificity and 54%accuracy, p=0.004 (left panel) and 
KRASG13D/G12V analysis predicts VEGF production < 1046 pg/mL, with 75.00% 
sensitivity, 78.95% specificity and 54%accuracy, p=0.02 (right panel), in 
hypoxic condition of growth.  
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No statistical correlation was detected between the genetic 
background and the ratio of VEGF values in hypoxic versus 
normoxic conditions (represented as VEGF Fold Induction in 
Figure 9), suggesting that none of the genetic determinants, among 
those analyzed, affect hypoxia-induced upregulation of VEGF 
production. 
Unlike what has been reported in literature, we did not observe IL-
6 expression into the culture medium, at least under the 
standardized culture conditions employed. Indeed, as shown in 
Figure 10, IL-6 was almost never detected in cell culture media as 
compared with a positive control.  
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Figure 9. Analysis of VEGF fold induction. A. VEGF fold induction of 29 
CRC cell lines. Fold induction values were obtained as VEGF values in 
hypoxia/VEGF values in normoxia. B. 29 CRC cell lines analyzed for their 
VEGF fold induction (shade of blue) and their genetic background of BRAF, 
KRAS and PI3K or PTEN protein lack expression (reported in red). 
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Figure 10. Analysis of IL-6 expression in 29 CRC cell lines. 29 cell culture 
media were analyzed by IL-6 ELISA assay; the results are expressed as pg/mL 
for 1x106 cells. 
 
 
4.4 BRAF inhibition modulates IL-8, but not VEGF, 
expression according to the genetic background.  
 
We then investigated the molecular and the functional effects of 
BRAF, MEK, ERK1/2 and PI3K/mTOR inhibitors in four different 
CRC cell lines, which differ for both BRAF and PTEN status. Cell 
lines were exposed to increasing concentrations of drugs for 24 h 
in serum-free medium and IL-8 release was detected by ELISA 
assay.  
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As shown in Figure 11, inhibition of MEK and ERK1/2 with 
trametinib and SCH772984, respectively, profoundly suppressed 
IL-8 expression in all the cell lines tested, suggesting that IL-8 is 
directly regulated by the MEK/ERK pathway regardless of the 
genetic background of the cells. On the contrary, BRAF mutational 
status profoundly influences the functional outcome of its selective 
inhibition by dabrafenib on IL-8 production: indeed, while in 
BRAFV600E cell lines IL-8 strongly decreases after dabrafenib 
treatment (Figure 11, left panels), in BRAF-wt cell lines IL-8 
increases (Figure 11, right panels), possibly as a consequence of 
the well-known paradoxical ERK activation observed in BRAF wt 
models in response to selective BRAF inhibition [58]. 
The PI3K/mTOR inhibitor gedatolisib did not significantly 
modulate IL-8 production, confirming that the IL-8 release is 
downstream the BRAF/MEK/ERK pathway.  
Similar results were obtained in X-MAN™ isogenic HCT116 cell 
lines: indeed, even if the effect of trametinib on IL-8 expression is 
not evident in HCT116 Parental, due the very low levels of IL-8 
released from untreated cells, in HCT116 PTEN-loss trametinib 
effectively inhibited IL-8 production; conversely, BRAF inhibition 
by dabrafenib strongly upregulated IL-8 production in CRC 
isogenic cell lines, regardless of PTEN status (data not shown).  
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Figure 11. Analysis of IL-8 expression after MEK, BRAF, ERK and 
PI3K/mTOR inhibition. Cells were treated with increasing concentration of 
drugs, as indicated. IL-8 expression was measured after 24 hours of treatment, 
by IL-8 ELISA assay. The percentage of IL-8 was obtained from pg/mL 
assuming the levels in control cells as 100%. Results represent the average of 
three independent experiments. 
 
 
In order to ascertain whether the pharmacological effects observed 
on IL-8 production were specific to the release of this chemokine 
and did not cross-modulate other chemo- and cytokines, we 
analyzed VEGF expression, by ELISA assay, under the same 
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culture and treatment conditions. As shown in Figure 12, pathways 
inhibitors did not significantly affect VEGF levels or 
increased/decreased its expression, regardless of the genetic 
background, confirming that the different modulation in response 
to BRAF/MEK/ERK inhibition is specific to IL-8. 
 
 
 
Figure 12. Analysis of VEGF expression after MEK, BRAF, ERK and 
PI3K/mTOR inhibition. Cells were treated with increasing concentration of 
drugs, as indicated. VEGF expression was measured after 24 hours of treatment, 
by VEGF ELISA assay. The percentage of VEGF was obtained from pg/mL 
assuming the levels in control cells as 100%. Results represent the average of 
three independent experiments. 
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In Figure 13, the functional effects of dabrafenib, trametinib and 
gedatolisib on viability and cell growth are shown: as expected, 
BRAF-wt cell lines are more resistant to dabrafenib treatment 
(IC50: 6.4358 µM and 8.47e+015 µM for SNU1047 and LS180, 
respectively), as compared to BRAFV600E cell lines (IC50: 0.0702 
µM and 0.1755 µM for SNU1235 and HT29, respectively), 
whereas PTEN-loss cell lines are more resistant to trametinib 
treatment (IC50: 565.098 nM and 19.1052 nM  for SNU1235 and 
SNU1047, respectively), as compared to PTEN wt cell lines (IC50: 
0.0018 nM and 1.7268 nM  for HT29 and LS180, respectively) 
[55]. No difference in response to gedatolisib with respect to the 
mutational state of BRAF and PTEN was observed (IC50: 100.783 
nM, 2.049e+004 nM, 121.632 nM and 111.694 nM for SNU1235, 
SNU1047, HT29 and LS180, respectively).  
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Figure 13. Cell viability after MEK, BRAF and PI3K/mTOR inhibition. 
Cells were treated with increasing concentration of drugs, as indicated, for 72 
hours. Effects on cell growth were monitored by Crystal Violet assay. The 
percentage of viability was represented as % of control, assuming the levels in 
control cells as 100%. Results represent the average of three independent 
experiments. 
 
 
4.5 Trametinib and dabrafenib transcriptionally 
regulate IL-8 expression.  
 
Given the different effects of trametinib and dabrafenib on the 
release of IL-8 in the culture supernatant in different BRAF/PTEN 
contexts, we then investigated if inhibitors of the MAPK pathway 
would directly affect transcription of the IL-8 gene [34]. To this 
purpose, we treated SNU1235 (BRAFV600E/PTEN-loss) and 
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SNU1047 (BRAF wt/ PTEN-loss) with a fixed dose of trametinib 
(10 nM) and dabrafenib (0.1 mM) that was previously 
demonstrated to be effective in modulating IL-8 release in the 
culture medium; IL-8 mRNA levels were then evaluated by 
quantitative RT-PCR at multiple times (1, 2, 4 and 6 hours). Even 
though the chemokine is not detectable in the medium before 21 
hours of serum-free medium culture (data not shown), the drug 
effects at the IL-8 mRNA level are already evident after 1 hour of 
treatment, suggesting that trametinib and dabrafenib differentially 
regulate IL-8 expression by interfering with its transcription. 
Indeed, as shown in Figure 14, the results of the time course of 
gene expression show that trametinib downregulated the 
expression of IL-8 in both analyzed cell lines; on the contrary, 
dabrafenib downregulated IL-8 levels in the BRAFV600E context 
and upregulated IL-8 levels in BRAF-wt cell line, in agreement 
with the results shown in term of protein release in the culture 
supernatant (see Figure 11). 
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Figure 14. IL-8 mRNA expression after MEK and BRAF inhibition. Cells 
were treated with the indicated concentration of drugs, for 1, 2, 4 and 6 hours. 
The presence of IL-8 was detected by real-time PCR in all cell lines. Results 
were evaluated as ΔΔct of IL-8 tested relative to RPL19 and expressed as the 
ratio assuming the levels in the control 0 h as 1.0. Results are representative of 
an experiment of three independent experiments. 
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4.6 Molecular analysis of ERK and STAT3 in response 
to targeted inhibitors. 
 
We recently observed from phosphoproteomic analysis, assessed in 
PTEN-wt and PTEN-loss contexts, that kinases of the JAK/STAT3 
pathway are potential points of interest in PTEN-loss context; 
moreover, phosphorylation of STAT3 on Ser727 controls a 
common set of genes encoding for cytokines and chemokines, such 
as IL-8 [55]. Consistent with a selective effect of STAT3 activity 
as an activator or repressor of transcription of specific 
chemokines/cytokines depending on PTEN status, de la Iglesia et 
al. have recently shown that STAT3 signaling induces IL-8 
expression only in PTEN-loss, but not in PTEN-competent, 
glioblastoma cells [35]. Due the effects of drugs observed on gene 
transcription, we hypothesized that STAT3 could be responsible 
for the modulation of IL-8 expression and we therefore 
investigated its role on the regulation of IL-8 expression. To this 
purpose, we assessed whether trametinib and dabrafenib treatments 
could influence the phosphorylation levels of STAT3, thus in turn 
causing a modulation of STAT3 activity.  
Western blot analysis, shown in Figure 15, show that p-ERK levels 
are downregulated in all cell line, regardless of the genetic 
background, after trametinib treatment; on the contrary, p-ERK 
levels are upregulated, both in BRAF-wt and BRAFV600E, in 
response to dabrafenib treatment. No significant modulations in 
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both p-STAT3 Ser727 and p-STAT3 Tyr705 levels have been 
observed, with the exception of the increased phosphorylation of p-
STAT3 Ser727 after dabrafenib treatment in BRAF-wt context.  
 
 
 
Figure 15. Analysis of protein expression after trametinib e dabrafenib 
treatment. Cells were treated with the indicated concentration of drugs. After 
24 hours, CRC cell lines were lysed and analyzed by Western Blotting using the 
indicated antibodies and b-actin was used as protein loading and blotting 
control. 
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We also analyzed the effects of two STAT3 inhibitors, with a 
different mechanism of action: stattic inhibits STAT3 activation 
and nuclear translocation, whereas S31-201 inhibits STAT3-
STAT3 complex formation, STAT3 DNA-binding and 
transcriptional activities [59, 60]. As shown in Figure 16, from a 
preliminary analysis of IL-8 ELISA assay, the two drugs seem to 
have only marginal effects on IL-8 expression, in BRAFV600E and 
BRAF-wt contexts. 
These data underline the necessity to further investigate the 
molecular mechanisms by which IL-8 is differentially expressed 
according to BRAF genetic background and after treatment with 
molecularly targeted inhibitors, in CRC cell lines. 
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Figure 16. Analysis of IL-8 expression after STAT3 inhibition. Cells were 
treated with the indicated concentration of drugs, as indicated. IL-8 expression 
was measured after 24 hours of treatment, by IL-8 ELISA assay. The percentage 
of IL-8 was obtained from pg/mL assuming the levels in control cells as 100%. 
Results are representative of an experiment of three independent experiments. 
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5 DISCUSSION AND CONCLUSIONS 
 
Mutational status in CRC is a strong predictor for overall survival, 
not only in the metastatic setting but also in earlier stages, and it is 
involved in drug resistance development. Furthermore, mutations 
are often used as a biomarker to select patients who would benefit 
from a specific therapeutic approach: indeed, in patients with 
metastatic CRC, overall survival has improved mainly due to the 
use of targeted therapies, but survival improvement is linked to 
proper selection of patients who could benefit from these 
treatments. For example, only patients lacking mutations in KRAS 
or NRAS benefit from EGFR monoclonal antibodies (cetuximab 
and panitumumab) treatment [9]. 
The general aim of our study was to assess how the genetic 
background of CRC cells, such as PI3KCA, PTEN, BRAF or 
KRAS status, influences the expression of chemokines and 
proangiogenic factors, which could, in turn, affect response to 
targeted therapies. 
Recently, we demonstrated that, in a panel of cancer cell lines with 
different histological origin, combined treatment with MAPK/PI3K 
inhibitors synergistically inhibits tumor growth only in PTEN-loss 
contexts [55]. Combination therapies could represent the best and 
most effective treatment option, in order to prevent drug resistance 
development in cancer cells during treatment, but imply increased 
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toxicity and financial costs and should be thus reversed to patients 
at the highest chance of benefit. Unfortunately, TME and TSI also 
increase drug-resistance development of cancer cells, thus leading 
to the need of better understanding of the mechanisms beyond 
acquired tumor-resistance, which remain crucial to determine 
overall patient benefit [61]. Albeit genetically “normal”, TME can 
be influenced by and respond to the genetic background of cancer 
cells with which it interacts and the molecularly targeted 
treatments applied, respectively, and play a critical role in therapy 
resistance and disease recurrence [62]. For example, in addition to 
the role in resistance to targeted therapy, PTEN-loss also leads to 
immunoresistance in several cancers with different histological 
origins [63]. Furthermore, interactions among cancer cells and 
between cancer cells and the surrounding microenvironment affect 
the sensitivity of the cells to targeted therapy and recent evidence 
from our group specifically showed that the interaction with the 
microenvironment depends on the genetic background of the tumor 
cells, in particular with regard to PTEN status [64]. 
Based on this evidence, we characterized a panel of 29 CRC cell 
lines for PTEN expression (Figure 3, Table 1) and investigated the 
role of PTEN status in the expression of specific 
chemokines/cytokines which may, in turn, affect the interaction of 
tumor cells with the surrounding microenvironment. From 
preliminary data, we observed that a different number of seeded 
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cells alters the expression of chemokines: to control for the 
influence of culture condition, we standardized the growth of CRC 
cell lines in terms of cell numbers, degree of confluence and 
chemokine/cytokine production expressed as pg/mL. In the panel 
of cell lines analyzed, we observed that both BRAFV600E and 
PTEN-loss status are significantly associated with higher levels of 
IL-8 production and release in the culture medium (Figure 4). 
Moreover, CRC cell lines release the highest levels of IL-8 in the 
presence of simultaneous BRAFV600E and PTEN-loss are co-
express (Figure 5); in the panel of cell lines analyzed, these two 
molecular alterations co-occur in 5 CRC cell lines and there is non-
significant trend co-occurrence in CRC specimens, accounting for 
an overall prevalence of BRAFV600E/PTEN-loss cases of 3% [65].  
IL-8 has tumorigenic and proangiogenic properties and it is 
associated with poor prognosis, due its effects on drug resistance 
development: for example, Ning and colleagues demonstrated that 
IL-8 overexpression decreases sensitivity to cytotoxic effects of 
oxaliplatin in CRC cells [46]. Moreover, Kopetz and colleagues 
demonstrated that increased secretion of IL-8 is associated with 
resistance to antiangiogenic therapy [66]. Rubie and colleagues 
also showed that there is an association between IL-8 production 
and progression of CRC, including metastasis development [51].  
Even though IL-8 plays a critical role in CRC progression, many 
other soluble factors are involved in TSI, such as VEGF and IL-6 
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[53, 67].  The importance of VEGF in CRC is underlined by the 
use of bevacizumab (and other VEGF-targeted agents) in clinical 
practice, in combination with chemotherapy, and several studies 
show that the clinical benefit from anti-VEGF therapy appears to 
be independent of KRAS status [68].  Due to VEGF relevance in 
CRC, and in order to highlight the specific correlation between IL-
8 and BRAFV600E and PTEN-loss, we also analyzed the expression 
of VEGF in the same standardized culture conditions of growth 
used for IL-8 analysis, and statistical data showed that the highest 
levels of VEGF are correlated with KRAS wild-type and PTEN-
loss status, in both normo- and hypoxic condition of growth 
(Figure 6-8). 
Due the association between IL-8 expression and 
BRAFV600E/PTEN-loss, we next investigated whether the specific 
background could otherwise influence the effects of molecular 
target inhibitors on the production of IL-8.  Consistent with the key 
role played by the MAPK pathway in modulating IL-8 expression, 
we chose to analyze the effects of BRAF (dabrafenib), MEK 
(trametinib) and ERK1/2 (SCH772984) inhibitors, on IL-8 
production [34]. Four different CRC cell lines, which differ for 
both BRAF and PTEN status were treated with the same 
concentration of drugs. Results show that trametinib downregulates 
the expression of IL-8, regardless of the genetic background 
(Figure 11), in correlation with p-ERK levels (Figure 15). 
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Conversely dabrafenib affects IL-8 production and release in the 
culture medium of CRC cells in a manner that is strictly dependent 
on BRAF mutational status: in BRAFV600E models, dabrafenib 
strongly downregulates IL-8 production (in a manner similar to 
what it is observed in response to trametinib); on the other hand, in 
BRAF-wt CRC models, dabrafenib consistently increases IL-8 
production regardless of PTEN status. Based on the tight 
association between modulation of p-ERK levels and IL-8 
production observed in response to the MEK inhibitor trametinib, 
we hypothesized that the differential effects of selective BRAF 
inhibition in BRAF-wt versus BRAFV600E contexts might be due to 
the well-described paradoxical ERK activation observed in 
response to BRAF inhibition on BRAF-wt contexts [69-72]. 
However, ERK phosphorylation analysis in the CRC models 
employed here clearly shows that dabrafenib elicits paradoxical 
ERK phosphorylation regardless of BRAF mutational status. Such 
relatively unexpected [73] finding raises two interesting 
hypotheses: 1) paradoxical ERK activation in response to BRAF-
selective inhibitors, such as dabrafenib, may  explain the clinical 
resistance of BRAFV600E CRC to BRAF-directed agents [74]; 2) 
regulation of IL-8 production has a complex relationship with ERK 
activation status and other mechanism cooperate with ERK activity 
to control IL-8 transcription and release. 
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Many groups showed that BRAFV600E CRCs express higher levels 
of EGFR, as compared to BRAF-wt CRCs [75], and that signaling 
from EGFR could lead to re-accumulation of p-ERK and resistance 
to EGFR-inhibitors [76]. Based on the observations described here 
and on literature data, we propose a working model whereby in 
BRAF-wt contexts dabrafenib causes paradoxical ERK activation 
(possibly further increased by contextual increased signaling 
through EGFR family members), thereby causing increased IL-8 
transcription, whereas trametinib shuts down ERK activation and 
IL-8 production (Figure 17, right panel). On the other hand, similar 
molecular mechanisms are in place in BRAFV600E CRC models in 
response to trametinib, resulting in ERK inhibition and decrease 
IL-8 production; however, in response to dabrafenib in BRAF-mut 
contexts, ERK activation is maintained by sustained signaling 
through EGFR family members despite BRAF inhibition and the 
observed decrease in IL-8 production is due to yet unknown 
mechanisms regulating gene transcription and/or RNA/protein 
stability (Figure 17, left panel). In that respect, preliminary data 
from our group show that the activation of EGFR family members 
(particularly EGFR and HER3) is consistently observed in 
response to dabrafenib in both BRAF-mut and -wt contexts in CRC 
models (Bazzichetto C., unpublished observations). 
We also confirmed that the effects of trametinib and dabrafenib on 
the expression of cytokines, related to the genetic background, 
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were specific to IL-8, by analyzing the effect of the same inhibitors 
on VEGF expression (Figure 12). We also analyzed the effects of a 
double inhibitor of both PI3K and mTOR (gedatolisib), and we 
didn’t observe any modulation in IL-8 expression after treatment, 
confirming that the MAPK pathway is more relevant in the 
regulation of IL-8, than PI3K/AKT. 
Many evidence show that IL-8 expression is regulated by 
modulation of gene transcription, and we previously reported that 
MEK inhibitors downregulate IL-8 expression at the transcriptional 
level [34]. Moreover, preliminary data show that IL-8 is 
downregulated in response to combined MAPK/PI3K inhibition, 
possibly as a consequence of increased STAT3 phosphorylation, 
both in melanoma and CRC cell models (Ciuffreda L., unpublished 
data). De la Iglesia and colleagues also showed a correlation 
between STAT3 and IL-8 in glioblastoma PTEN-loss context: 
indeed, the transcription factor STAT3 negatively regulated IL-8 
transcription only in PTEN-loss context, suggesting that the 
genetic background could specifically affect the transcription of 
IL-8 [35].  We observed that trametinib and dabrafenib treatment 
regulates IL-8 expression via transcription modulation (Figure 14), 
and that STAT3 could positively regulate IL-8 gene transcription 
only in BRAF-wt context (Figure 16). However, both molecular 
and functional data highlight a relatively minor involvement of the 
STAT3 pathway in the regulation of IL-8 production in response to 
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MAPK pathway inhibitors in preclinical models of CRC (Figure 
17). 
 
 
 
Figure 17. Feedback reactivation of MAPK signaling and schematic 
regulation of IL-8 transcription. The RAS-RAF-MEK-ERK cellular signaling 
cascade couples extracellular signals to transcription factors, regulating gene 
expression. After external stimuli (i.e. growth factors), RTKs and RAS are 
activated: RAS activates and binds the protein kinase RAF, RAF kinase 
phosphorylates and activates MEK, which in turn phosphorylates and activates 
ERK, which translocates into the nucleus and regulates gene transcription.   
Upon addition of the BRAF inhibitor dabrafenib, signaling output from 
BRAFV600E is blocked and there is a transient suppression of ERK activation and 
MAPK signaling, However, EGFR and other RTKs drive feedback activation of 
RAS and CRAF, leading to reactivation of ERK and restoration of MAPK 
signaling. In this genetic context, other transcriptional factors, such as STAT3 
could negatively regulate IL-8 transcription, even in presence of p-ERK in the 
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nucleus. On the contrary, in BRAF wt contexts, even in presence of dabrafenib, 
BRAF forms a complex with CRAF and hyperactivates CRAF istelf, thereby 
driving paradoxical hyper-activation of both MEK and ERK. p-ERK 
translocates in the nucleus and IL-8 expression is upregulated. 
Trametinib inhibits MEK activity, thus in turn downregulates p-ERK levels: 
ERK remains in cytoplasm compartment and IL-8 gene is not transcript, 
regardless of the genetic status of BRAF (bottom panels). 
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6 FUTURE PROSPECTS 
 
The work conducted so far demonstrates that IL-8 production is 
strongly associated with BRAFV600E and PTEN-loss in CRC 
models and that its production is mostly regulated through 
activation of the MAPK, rather than the PI3K/AKT pathway; such 
regulation is specific to IL-8, as other pro-angiogenic cytokines, 
such as IL-6 or VEGF, are either absent (IL-6) or regulated by 
different mechanisms as compared with IL-8 production (VEGF). 
The ability to correlate molecularly defined subclasses of CRC 
with a specific chemokine/immunologic profile(s) will potentially 
allow to identify resistance mechanisms and to determine what 
patients could benefit from specific signaling inhibitors. To 
investigate the role of IL-8 in modulating the response to target 
inhibitors, we will analyze how IL-8 is involved in the growth of 
CRC cells and how it could interfere with drug response to target 
therapy, both with/without the addition of recombinant human IL-
8, which activate its downstream pathways, and anti-IL-8 human 
antibodies, that can neutralize the effects of IL-8 released in the 
culture media by CRC cells. 
Stromal cells also release soluble factors in the TME, thus in turn 
influencing drug response. To investigate the role of fibroblast 
cells in TSI, we propose to analyze how conditioned medium (CM) 
of the cells could influence the growth of CRC cells and how the 
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presence of stromal cells could interfere with the response of CRC 
cells to target therapies (presence/ absence of CM, co-culture 
system, invasion and migration assays). 
2D cell monolayer culture techniques do not reflect the real cancer 
tissue and microenvironment. In order to guarantee that data 
gathered in vitro are predictive of the in vivo system, we propose to 
conduct the analysis of IL-8 expressed in tissue and serum/plasma 
of patients, affected by CRC at different stages. To this purpose, 
we are now setting antibodies for IL-8 and PTEN protein 
expression, to analyze 184 tissue microarray (TMA) by 
immunohistochemistry (IHC) (Figure 18). 
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Figure 18. Immunohistochemistry analysis of PTEN and IL-8. 
Immunohistochemical expression of PTEN and IL-8 in both RKO cell lines (A) 
and TMA (B) (images were obtained at 40x magnification using a light 
microscope equipped with a software able to capture images (DM2000 LED, 
Leica)). 
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